Nascent Biotech, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

North palm beach, fl / accesswire / april 16, 2024 / nascent biotech, inc. (otcqb:nbio) ("nascent biotech", "nascent", or the "company"), a clinical-stage biotechnology company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturing run to ensure pritumumab ("ptb") supplies are at maximum potency when patient dosing begins in the upcoming phase ii clinical trial. "taking the time to navigate this opportunity with proper care and diligence is a step that demonstrates our commitment to the best interests of our investors, partners, shareholders, and potential future patients," remarked sean carrick, ceo of nbio.

North palm beach, fl / accesswire / march 19, 2024 / nascent biotech, inc. (otcqb:nbio) ("nascent biotech", "nascent", or the "company"), a clinical-stage biotechnology company developing monoclonal antibodies targeting various cancer types, and hypospray pharma ("hypospray®"), a clinical and commercial stage drug delivery technology company, announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from pritumumab ("ptb"), nascent's lead monoclonal antibody cancer treatment asset, which is now in phase ii clinical research for the treatment of brain cancer. once successfully commercialized, the company hopes to eliminate bi-weekly weekly infusions, allowing patients to administer pritumumab and avoid inconvenient, tedious, and uncomfortable multi hour cancer center treatment visits.

North palm beach, fl and new york, ny / accesswire / february 6, 2024 / nascent biotech, inc. (otcqb:nbio) ("nascent biotech", "nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with manhattan biosolutions, inc. (manhattan bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (adcs) using nascent's lead clinical candidate pritumumab (ptb) as the tumor-targeting antibody element. pritumumab (ptb) is a natural human antibody.

Analysts suggest nascent value at $0.60 to $2.84 per share north palm beach, fl / accesswire / january 9, 2024 / nascent biotech, inc. (otcqb:nbio) ("nascent biotech", "nascent", or the "company"), a clinical-stage biotechnology company developing monoclonal antibodies focused on treating various cancers, announced today that the company was featured in an independent research report by marble arch research the report can be viewed on the company web site at: https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/ nascent ceo sean carrick remarked, "we are pleased to be featured in this independent prospective of nascent's investment potential. this report underscores our internal conviction that the company's common stock is presently undervalued.

North palm beach, fl / accesswire / december 19, 2023 / nascent biotech, inc. (otcqb:nbio) ("nascent biotech", "nascent", or the "company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that the company has completed payment of all outstanding variable convertible debt obligations. on august 30, 2023, the company and the noteholder ya ii pn, llc agreed to terms that fully satisfy the company's outstanding obligation with respect to the related note.

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster presentation, entitled "Phase I Study of Pritumumab in Brain Cancer", will take place from 1:15-4:15 PM CDT on June 3rd, during the "Central Nervous Systems Tumors" session in Hall A of McCormick Place Convention Center.

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions (together, the "Partners"), are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners. Under a research collaboration agreement signed in 2020, Nascent Biotech and Manhattan BioSolutions partnered to discover and develop a safe and affordable COVID-19 vaccination platform based on modifying licensed BCG vaccine technology originally developed for Tuberculosis ("TB"), but with broader utility in protecting against infection from other types of viruses, some of which may have the potential to cause major outbreaks in humans.

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a "Speculative Buy" under its tiered rating system, and specified a price target of between $0.39-$1.99. The full research report may be found at: https://www.nascentbiotech.com/wp-content/uploads/2021/06/marble-arch-report-6.10.21.pdf The report concludes, "We believe that there is a reasonable investment thesis at hand to indicate that the company's market value can rise significantly as its lead development drug, PTB, progresses through its clinical study journey, which has just begun.

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company") has entered into a license agreement (the "Agreement") with BioRay Pharmaceutical Co Ltd ("BioRay"), thereby granting to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the "Note") held by Harbor Gate Capital LLC ("Harbor Gate"). Under the terms of the Note, Harbor Gate had the right to redeem the outstanding liability in the form of an equity conversion that presented dilution risk for Nascent shareholders.

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that It has paid off and eliminated a major convertible debt note, pre-emptively preventing a dilutive conversion. The note, which was held by JSJ Investments, LLC ("JSJ"), represented over $186k in debt carried pre-conversion on the Company's balance sheet.

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Patient enrollment remains open, and the trial continues to recruit new patients for participation.

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Screening to enroll patients in the trial is already underway.

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a "Method-of-Use" patent by the US Patent and Trademark Office ("USPTO") for their primary asset, Pritumumab ("PTB"). Specifically, the patent approval is related to PTB's ability to cross the Blood-Brain Barrier ("BBB").